The promoter region for IgE contains binding elements for the transcription factors signal transducer and activator of transcription (STAT) 6, nuclear factor (NF)-?B/Rel, PU.1, and C/EBP. STAT6 appears to be the pivotal transcription factor responsible for mediating IL-4-induced activation of IgE transcription. Because the STAT6 binding site and the composite PU.1/NF-?B1 element in the IgE germline promoter are composed of a DNA polypurine stretch, the authors examined the possibility that 2'-aminoethoxy-modified triplex-forming oligonucleotides (TFOs) complementary to this region could be used to form inhibitory DNA triplex structures.
Significant findings
TFOs formed DNA triple-helix structures and inhibited the interaction of STAT6, NF-?B, and PU.1 in a dose-dependent fashion with high specificity and selectivity. In addition, the IL-4-induced activity of the IgE germline promoter was blocked. These data support the concept of specific modulation of gene expression by DNA triplex formation induced with chemically modified oligonucleotides.
Comments
Recently acquired knowledge of normal and 'disease' gene DNA sequences has provided an opportunity for the highly rational design of therapeutic agents that act at the DNA level through sequence-specific interactions. Among the ligands capable of binding DNA in a precise, sequencespecific manner are TFOs. In this study, the authors have shown that TFOs can perturb transcription factor binding and thus effectively inhibit IL-4-induced IgE promoter activity in B cells. Although further studies are required to examine the effectiveness of these oligonucleotides on IgE production in vitro and in vivo, this study shows that gene targeting agents, such as TFOs, represent new opportunities for rational drug development in asthma and allergy.
